» Articles » PMID: 38165143

3D-printed Microfluidic Device for High-throughput Production of Lipid Nanoparticles Incorporating SARS-CoV-2 Spike Protein MRNA

Overview
Journal Lab Chip
Specialties Biotechnology
Chemistry
Date 2024 Jan 2
PMID 38165143
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid nanoparticles (LNPs) are drug carriers for protecting nucleic acids for cellular delivery. The first mRNA vaccines authorized by the United States Food and Drug Administration are the mRNA-1273 (Moderna) and BNT162b (BioNTech/Pfizer) vaccines against coronavirus disease 2019 (COVID-19). We designed a 3D printed Omnidirectional Sheath-flow Enabled Microfluidics (OSEM) device for producing mRNA-loaded LNPs that closely resemble the Moderna vaccine: we used the same lipid formulations to encapsulate mRNA encoding SARS-CoV-2 spike protein. The OSEM device is made of durable methacrylate-based materials that can support flow rates in the mL min range and was fabricated by stereolithography (SLA), incorporating readily adaptable interfaces using commercial fluidic connectors. Two key features of the OSEM device are: 1) a 4-way hydrodynamic flow focusing region and 2) a staggered herringbone mixer (SHM). Superior to conventional planar fluid junctions, the 4-way sheath flow channel generates an evenly focused, circular center flow that facilitates the formation of LNPs with low polydispersity. Downstream, fluid mixing in the SHM is intensified by incorporating a zig-zag fluidic pathway to deliver high mRNA encapsulation efficiency. We characterized the mRNA-loaded LNPs produced in the OSEM device and showed that the enhanced 3D microfluidic structures enable a 5-fold higher throughput production rate (60 mL min) of LNPs compared to commercial multi-thousand-dollar micromixers. The device produced LNPs of diameter less than 90 nm, with low polydispersity (2-8%) and high mRNA encapsulation efficiency (>90%). The 3D-printed device provides a cost-effective and easily prepared solution for high-throughput LNP production.

Citing Articles

Applications of microfluidics in mRNA vaccine development: A review.

Fardoost A, Karimi K, Govindaraju H, Jamali P, Javanmard M Biomicrofluidics. 2024; 18(6):061502.

PMID: 39553921 PMC: 11567697. DOI: 10.1063/5.0228447.

References
1.
De R, Mahata M, Kim K . Structure-Based Varieties of Polymeric Nanocarriers and Influences of Their Physicochemical Properties on Drug Delivery Profiles. Adv Sci (Weinh). 2022; 9(10):e2105373. PMC: 8981462. DOI: 10.1002/advs.202105373. View

2.
Evenson W, Lin W, Pang K, Czaja A, Jalali-Yazdi F, Takahashi T . Enabling Flow-Based Kinetic Off-Rate Selections Using a Microfluidic Enrichment Device. Anal Chem. 2020; 92(15):10218-10222. PMC: 10368462. DOI: 10.1021/acs.analchem.0c01867. View

3.
Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078-1094. PMC: 8353930. DOI: 10.1038/s41578-021-00358-0. View

4.
Singh R, Lillard Jr J . Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009; 86(3):215-23. PMC: 3249419. DOI: 10.1016/j.yexmp.2008.12.004. View

5.
Lin W, Malmstadt N . Liposome production and concurrent loading of drug simulants by microfluidic hydrodynamic focusing. Eur Biophys J. 2019; 48(6):549-558. DOI: 10.1007/s00249-019-01383-2. View